ERBB2 and breast carcinoma: One of the summits in the breast tumor sample absent from the colon tumor sample corresponds to the bidirectional promoters of MED1 and CDK12, both of which have been shown to functionally cooperate with co-amplified ERBB2 in aggressive breast cancer (26, 27).